Profil
Advanced Cell Technology ist ein Biotecknik-Unternehmen, dass sich auf die Anwendung von Stammzelltechnologie im Bereich von Regenerative-Medizin konzentriert.
Aktienkurs
gründliche Analyse
Aktuelle Nachrichten von Advanced Cell Technology
Vorstellungen
Keine Unterlagen verfügbar.
Verbundene Recherche
Keine Unterlagen verfügbar.
Unternehmensstrategie und – daten:
Pencari Mining Corporation is an exploration and development company traded on the TSX Venture Exchange (symbol: PMC) headquartered in Vancouver, B.C., Canada. Pencari's strategic focus is on uranium and gold projects. Pencari has taken this focus to Madagascar, where there are abundant unexplored opportunities. Pencari controls 5 gold properties totalling 4,788.5 square kilometres and 8 uranium properties totalling 27,518.75 square kilometres. Pencari's total land position in the central, western, and southern regions of Madagascar that are prospective for gold and uranium is 32,307.25 square kilometres. Pencari continues to look for additional opportunities. In addition, Pencari has a 90% interest in a joint venture on the Pani property, Indonesia.
Aktuelle Tätigkeiten:
Our Technology
Advanced Cell Biotechnology
Advanced Cell’s technologies could provide therapies for a broad range of diseases, including myoblasts for treating heart failure; hemangioblasts for treating blood disorders, cardiovascular disease, and cancer; retinal pigment epithelial cells for treating macular degeneration and other retinal degenerative disorders; skin cells for dermatological conditions; neuronal cells for spinal cord injury; and liver cells for hepatitis and cirrhosis.
Most of the body’s specialized cells cannot be replaced by natural processes if they are seriously damaged or diseased. Stem cells can be used to generate healthy and functioning specialized cells, which can then replace diseased or dysfunctional cells. Replacing diseased cells with healthy cells, called cell therapy, is similar to the process of organ transplantation. Some conditions or injuries can be treated through the transplantation of entire healthy organs, but there is an acute shortage of donors. Stem cells can serve as an alternate and renewable source for specialized cells.
Currently, researchers are investigating the use of adult, fetal and embryonic stem cells as a resource for various specialized cell types such as nerve cells, muscle cells, blood cells and skin cells. Adult stem cells do not require the manipulation or destruction of an embryo thus they lack the controversy surrounding embryonic stem cell research, but the cells are limited in their ability to differentiate into different cell types.
Embryonic stem cells, while limited in use because of the current political and ethical debate, can develop into one of over 200 cell types in the body when given the necessary stimulation (i.e., they are totipotent). ACT is using a combination of embryonic and adult stem cell technologies to develop novel therapies for indications with few or no alternatives.
To find out more CLICK HERE
Regenerative Medicine
The emerging field of treatment called “regenerative medicine” or “cell therapy” refers to treatments that are founded on the concept of producing new cells to replace malfunctioning or damaged cells as a vehicle to treat disease and injury. Our focus is the development of effective methods to generate replacement cells from stem cells. Many significant and currently untreatable human diseases arise from the loss or malfunction of specific cell types in the body.
This is especially true of diseases associated with aging such as Alzheimer’s disease, Parkinson’s disease, type II diabetes, heart failure, osteoarthritis, and aging of the immune system, known as immunosencence. This is also true for medical conditions resulting from damage to cells due to acute disease, such as trauma, infarction and burns. We believe that replacing damaged or malfunctioning cells with fully functional ones may be a useful therapeutic strategy in treating many of these diseases and conditions.
To find out more CLICK HERE
Research Programs
Blastomere Program
In August 2006, Advanced Cell Technology reported that company scientists had successfully generated human embryonic stem cells (hESCs) using an approach that does not destroy the developmental potential of embryos. The technique was reported in an article appearing in the journal Nature. The article described a method for deriving stem cells from human blastomeres with a single-cell biopsy technique called Preimplantation Genetic Diagnosis (PGD). This technique is used in in vitro fertilization (IVF) clinics to assess the genetic health of preimplantation embryos.
The cell lines produced using this technique appeared to be identical to hESC lines derived from later stage embryos using techniques that destroy the embryo’s developmental potential. ACT had previously reported the successful use of a similar technique in mice in Nature in October 2005. To create hESC lines, the researchers used single cells obtained from unused embryos produced by IVF for clinical purposes. Nineteen stem-cell outgrowths and two stable hES cell lines were obtained. These cell lines were genetically normal and retained their potential to form all of the cells in the human body, including nerve, liver, blood, vascular, and retinal cells that could potentially be used to treat a range of human diseases.
To find out more CLICK HERE
Cellular Reprogramming
This research program involves development of therapies based on the use of genetically identical pluripotent stem cells generated by our cellular reprogramming technologies. These technologies can be used to generate patient-specific pluripotent cells and tissues for transplantation. We believe our technology platform will enable the transformation of a patient’s cell into pluripotent ES cells that are histocompatible with the patient and have the potential to be differentiated into any of the over 200 different human cell types that may be therapeutically relevant in treating diseased or destroyed tissues in human patients.
We expect that our cellular reprogramming technologies will offer a new avenue for the introduction of targeted genetic modifications in cells and for the regeneration of cell lifespan, thereby making youthful cells available for aging patients. The combination of these advances, the ability to produce young cells of certain kinds that are histocompatible with the patient, is a core potential application of our technology. We believe these cellular reprogramming technologies will be effective therapies where there is time to prepare customized therapy through reprogramming of the patient’s own cells.
To find out more CLICK HERE
Stem Cell Differentiation
Regenerative medicine requires that stem cells, from whatever source derived, be differentiated (or re-differentiated) into specific body cell types and then physically transplanted into a patient. Differentiation into tissues such as cardiac muscle, blood, and other tissues occurs spontaneously in ES cells being cultured in a dish. Successful application of stem cell technology will require control over the specific kinds of cells into which stem cells differentiate. Control of differentiation and the culture and growth of stem and differentiated cells are important current areas of research for us.
To find out more CLICK HERE
Also, some chemicals, such as retinoic acid, can be used to trigger differentiation into specific cell types such as nerve cells. We intend to pursue differentiation approaches both in-house and through collaborations with other researchers who have particular interests in, and skills related to, cellular differentiation. These efforts include using both animal and human stem cell lines. Our research in this area includes projects focusing on developing many different cell types that may be used in the future to treat a wide range of diseases. Currently researchers at the company are working on projects to generate stable cell lines including retinal pigment epithelium (“RPE”) cells, skin cells, and hemangioblast cells. In the future, researchers at the company may also focus on various projects to generate other cell types, including neuronal, lung, heart, liver and pancreatic beta cells.
Intellectual Property
Our research and development is supported by a broad intellectual property portfolio. We currently own or have exclusive licenses to over 30 patents and 380 patent applications pending worldwide in the field of regenerative medicine and stem cell therapy. We also have non-exclusive rights to a portfolio of patents and patent applications that support our core intellectual property. We believe our intellectual property collectively represents one of the strongest portfolios in the field.
To find out more CLICK HERE
To see ACT's Stem Cell-Related Research Pipeline CLICK HERE
Management
Senior Executive Officers
William M. Caldwell, IV - Position: Chairman and CEO
Mr. William Caldwell serves as Chairman and Chief Executive Officer of the Company and has a 30-year management career working with emerging technologies and restructuring distressed corporate environments. During his career, he has served in senior executive positions both in marketing and finance. He has worked with Booz Allen and Hamilton; the Flying Tiger Line Inc.; Van Vorst Industries; and Kidder Peabody. He started a firm specializing in corporate financial and strategy planning, which was instrumental in restructuring over $1.0 billion of debt for over twenty companies and partnerships. He was a pioneer in the satellite radio auctions as president of Digital Satellite Broadcasting Corporation; assisted in the financing, and became president and ultimately CEO in the restructuring of CAIS Internet. He has advised corporations, both public and private, in technology, telecommunications, retailing, real estate, hospitality, publishing, and transportation. He received his B.A. degree from the University of Southern California and was a Multinational Enterprise Fellow at the Wharton Graduate School of Finance. He serves as a director of Lee Pharmaceuticals (LPHM.PK) and King Koil Franchising Corp.
Robert Lanza, M.D. - Position: Chief Executive Officer
Dr. Lanza joined ACT in 1999. Dr. Lanza has over 25 years of research and industrial experience in the area of stem cells and regenerative medicine. From 1990 to 1998, he was Director of Transplantation Biology at BioHybrid Technologies, Inc., and is currently an Adjunct Professor at the Institute for Regenerative Medicine, Wake Forest University School of Medicine. He has several hundred scientific publications and patents, and has authored/edited 20 books, including the “Handbook of Stem Cells” (as Editor-in-Chief), Principles of Tissue Engineering, XENO, the Yearbook of Cell & Tissue Transplantation, and One World: The Health & Survival of the Human Species in the 21st Century (as editor, with forewords by C. Everett Koop and former President Jimmy Carter). He is a former Fulbright Scholar, and studied as a student in the laboratory of Richard Hynes (MIT), Jonas Salk (The Salk Institute), and Nobel laureates Gerald Edelman (Rockefeller University) and Rodney Porter (Oxford University). He also worked closely (and coauthored a series of papers) with the late Harvard psychologist B.F. Skinner and heart transplant pioneer Christiaan Barnard. Dr. Lanza received his B.A. and M.D. Degrees from the University of Pennsylvania, where he was both a University Scholar and Benjamin Franklin Scholar.
Edmund Mickunas
Position: Vice President of Regulatory
Mr. Mickunas, a recent addition to the ACT team, is the Company’s Vice President of Regulatory. Mr. Mickunas is in charge of spearheading the company’s effort to translate its cutting edge research into FDA approved therapies ready for clinical trials. Mr. Mickunas is working with Dr. Robert Lanza and ACT’s Development Team to finalize and submit the IND for the RPE program to the FDA. Mr. Mickunas brings 28 years of experience from a number of disciplines including biotechnology, medical device and pharmaceuticals. He has worked in preclinical program development, clinical affairs, regulatory affairs/compliance and quality assurance, and has worked closely with all disciplines involved in product development. Prior to joining Advanced Cell, Mr. Mickunas was Executive Director, Regulatory Affairs and Quality Assurance for Applied Genetic Technologies Corporation, a privately held gene therapy and genomics-focused biotech company. Mr. Mickunas was previously Senior Director of Regulatory Affairs and Compliance for Control Delivery Systems, Inc., where he managed the submissions of IND filings, among other responsibilities. He also held senior regulatory positions at Bioheart, Inc., Cytomed and Del Laboratories. He received his B.S. and pursued graduate studies in human biochemistry at Fairleigh Dickinson University, as well as a Masters Degree from Fairfield University.
Roger Gay, Ph.D
Position: Senior Director of Manufacturing
Dr. Gay serves as Advanced Cell’s Senior Director of Manufacturing. Dr. Gay is responsible for Process Development and Clinical Manufacturing at Advanced Cell. For the past 28 years, he has been involved in clinical manufacturing and product development at a number of biotechnology companies specializing in cell-based products and services including Organogenesis, Diacrin, Genvec and Mytogen. He has extensive experience directing and leading product development and clinical trial manufacturing for cellular products having planned and executed R&D programs leading to market introduction of first-ever products for two biotechnology companies prior to joining Advanced Cell. He received a Ph.D. in biochemistry from the University of Rochester in 1980 and was a post-doctoral fellow at Harvard Medical School.
Rita Parker
Position: Director of Operations
With Advanced Cell since 2005, Ms. Parker brings a 20 year career in management to her role as the Company’s Director of Operations. A native of Massachusetts, she has held senior positions in marketing and operational management, focusing on paving the way for local businesses to expand their geographical footprint and increasing their technological and productive capabilities by introducing new and efficient information technology products and systems; a few of these companies include Digital Equipment Corporation, Computer Devices, and Banyan Systems, Inc.
For more information on the Board of Directors CLICK HERE
For more information on the Ethics Advisory Board CLICK HERE
Hauptaktionäre
For shareholder information CLICK HERE
Kontakt
Company Headquarters
Advanced Cell Technology, Inc.
P.O. Box 1700
Santa Monica, CA 90406
Tel: (310) 576 0611
Fax: (310) 576 0662
info@advancedcell.com
Massachusetts Laboratory Facility
33 Locke Dr.
Marlborough, MA 01752
Tel: (508) 756-1212
Fax: (508) 229-2333
Investor Relations
Dan Schustack
dschustack@ceocast.com
(212) 732-4300
Media Relations
Bill Douglass
Gotham Communications, LLC
(646)450-3615
bill [at] gothamcomm [dot] com
Human Resources
careers@advancedcell.com
Unternehmensinformationen
No info available.
Anleger, die in Advanced Cell Technology interessiert sind, haben auch angesehen:
- Alliance Pharma plc (AIM: APH)
- Ariana Resources (AIM: AAU)
- Golden State Resources (ASX: GDN)
- Goldplat (AIM: GDP)
- Kryso Resources (AIM: KYS)
- Metals Exploration (AIM: MTL)
- Minera IRL (AIM: MIRL)
- Norseman Gold (AIM / ASX: NGL / NGX)
- OXUS GOLD (AIM: OXS)
- Pan African Resources (AIM: PAF)
- Patagonia Gold (AIM: PGD)
- Persian Gold (AIM: PNG)
- ReNeuron (AIM: RENE)
- Republic Gold (ASX: .RAU)
- Solomon Gold (AIM: SOLG)
- Stratex International (AIM: STI)
- Vatukoula Gold Mines (AIM: VGM)
